Scott Schliebner

EVP, Clinical Development Services

Scott Schliebner is the Senior Vice President of Clinical Development Services at TFS Health Science.

As a clinical development executive with a 25+ year background in drug development, Scott has focused on developing innovative solutions and strategic considerations to better engage, support, and include patients in the drug development lifecycle.  Mr. Schliebner’s efforts are focused on patient-centered approaches to drug development, reducing the burden of clinical trial participation, and leveraging novel and disruptive technologies to bring new therapies to patients faster.  Having held numerous leadership positions across the biotech, pharma, CRO, and non-profit sectors, Scott has developed a particular expertise in the study of rare diseases and the development of orphan drugs.

Additionally, Mr. Schliebner serves on the Board of Directors for Uplifting Athletes and Angel Aid.  Scott also supports early-stage entrepreneurs as a Strategic Advisor to Halo Health Systems, Jeeva Bioinformatics, and Atomic Medical Innovations.  Scott regularly works with rare disease patient-focused organizations, patient advocacy groups, drug development institutes, and academic research centers, in a collaborative commitment to further drug development.  Scott received a master’s degree in public health focused on epidemiology from the University of Utah School of Medicine and completed a Graduate Research Fellowship at The National Institutes of Health.